4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

4 - Neurogene Inc. (0001404644) (Issuer)

8-K - Neurogene Inc. (0001404644) (Filer)

SCHEDULE 13G/A - Neurogene Inc. (0001404644) (Subject)

424B5 - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

10-Q - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

SCHEDULE 13G - Neurogene Inc. (0001404644) (Subject)

SCHEDULE 13G/A - Neurogene Inc. (0001404644) (Subject)

Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00

Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

Robert W. Baird initiated coverage of Neurogene with a rating of Outperform and set a new price target of $54.00

Leerink Partners initiated coverage of Neurogene with a rating of Outperform and set a new price target of $46.00

William Blair initiated coverage of Neurogene with a rating of Outperform and set a new price target of $61.00

Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV administration is superior to IT-L in reaching key brain regions underlying Rett syndrome As previously reported, the first four participants in the NGN-401 Phase 1/2 trial gained 23 developmental milestones/skills, representing multi-domain improvement that requires transduction of key brain regions and nervous system The preclinical data also provide evidence-based confirmation that ICV and IT-L administration result in comparable peripheral organ transduction, showing n

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to imp

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company's common stock to four new employees (the "Inducement Grants") on October 1, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance w

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 47,040 shares of the Company's common stock to six new employees (the "Inducement Grants") on September 3, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance

Announced design of Embolden™ registrational clinical trial of NGN-401 gene therapy for Rett syndrome; trial initiation activities underway Completed dosing in Phase 1/2 NGN-401 trial, and remains on track to report updated clinical efficacy and safety data in the second half of 2025 Cash runway into early 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. "In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed d

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 27,480 shares of the Company's common stock to seven new employees (the "Inducement Grants") on August 6, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,290 shares of the Company's common stock to two new employees (the "Inducement Grants") on July 3, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with

Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill by video capture Written agreement from FDA to evaluate NGN-401 in females with Rett syndrome ages 3 years and older based on natural history study analysis Registrational trial initiation activities underway Phase 1/2 trial fully enrolled, with 5 participants dosed in 1H 2025, showing no evidence of HLH/hyperinflammatory syndrome at 1E15 vg dose Cash runway extended into early 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance wit

Oral presentation at ASGCT Annual Meeting to describe algorithm to monitor, detect and treat HLH, which can be adopted for AAV gene therapy Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic exposure to high doses of adeno-associated virus (AAV) gene therapy (>1E14 vg/kg). The

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)